sphingosyl-beta-glucoside and Intestinal-Obstruction

sphingosyl-beta-glucoside has been researched along with Intestinal-Obstruction* in 1 studies

Other Studies

1 other study(ies) available for sphingosyl-beta-glucoside and Intestinal-Obstruction

ArticleYear
Abdominal lymphadenopathy in children with Gaucher disease: Relation to disease severity and glucosylsphingosine.
    Pediatric hematology and oncology, 2022, Volume: 39, Issue:4

    Few case reports and series reported abdominal lymphadenopathy (ALN) in people with Gaucher disease (GD). However, it's prevalence among Gaucher population, clinical implications and potential biomarkers are unknown. Hence this study aims to assess the prevalence of ALN among children with GD & to correlate it to neutrophil-lymphocytic-ratio (NLR), platelet-lymphocytic-ratio (PLR) and glucosylsphingosine (Lyso-GL1). Fifty children with GD (14 type-1 and 36 type-3) on enzyme-replacement therapy (ERT) were compared to 50 matched healthy controls, focusing on history of pressure manifestations by ALN (diarrhea, constipation, abdominal pain, intestinal obstruction), and history of splenectomy, with calculation of severity scoring index (SSI). NLR, PLR and Lyso-GL1 were measured. Abdominal-ultrasound was done with assessment of liver and spleen volumes and ALN. CT-scan was done for those having significant lymphadenopathy. Twenty-six children with GD had ALN (52%). The most common presentations were abdominal-pain (22%) & constipation (18%), with intestinal-obstruction in 3 children (6%). Children with GD had significantly higher NLR (

    Topics: Biomarkers; Child; Constipation; Gaucher Disease; Humans; Intestinal Obstruction; Lymphadenopathy; Psychosine; Severity of Illness Index

2022
chemdatabank.com